Prx1 modulates the chemosensitivity of lung cancer to docetaxel through suppression of FOXO1-induced apoptosis

International Journal of Oncology

Volumn 43, Issue 1, 2013, Pages 72-78

  Hwang, Ki Eun ^a   Park, Do Sim ^b   Kim, Young Suk ^a   Kim, Byoung Ryun ^a   Park, Seong Nam ^a   Lee, Mi Kyung ^a   Park, Seong Hoon ^a   Yoon, Kwon Ha ^a   Jeong, Eun Taik ^a   Kim, Hak Ryul ^a  

^a Wonkwang University   (South Korea)

^b Wonkwang University School of Medicine   (South Korea)

Author keywords

Akt; Docetaxel; FOXO1; Lung cancer; Prx1

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CASPASE; DOCETAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR FKHR;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL LYSATE; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOTOXICITY; GROWTH RATE; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG CANCER; MODULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR XENOGRAFT; WESTERN BLOTTING;

APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; FORKHEAD TRANSCRIPTION FACTORS; HOMEODOMAIN PROTEINS; HUMANS; LUNG NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; TAXOIDS;

EID: 84879651288     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.1918     Document Type: Article

References (47)

1. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics. CA Cancer J Clin 60: 277-300, 2010.
2. Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M and Tanimoto M: Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 22: 3852-3859, 2004. (Pubitemid 41079865)
3. Ree SG, Kang SW, Chang TS, Jeong W and Kim K: Peroxiredoxin, a novel family of peroxidases. IUBMB Life 52: 35-41, 2001. (Pubitemid 33769667)
4. Yanagawa T, Ishikawa T, Ishii T, Tabuchi K, Iwasa S, Bannai S, Omura K, Suzuki H and Yoshida H: Peroxiredoxin I expression in human thyroid tumors. Cancer Lett 145: 127-132, 1999. (Pubitemid 29459080)
5. Yanagawa T, Iwasa S, Ishii T, Tabuchi K, Yusa H, Onizawa K, Omura K, Harada H, Suzuki H and Yoshida H: Peroxiredoxin I expression in oral cancer: a potential new tumor marker. Cancer Lett 156: 27-35, 2000. (Pubitemid 30326764)
6. Noh DY, Ahn SJ, Lee RA, Kim SW, Park IA and Chae HZ: Overexpression of peroxiredoxin in human breast cancer. Anticancer Res 21: 2085-2090, 2001.
7. Lehtonen ST, Svensk AM, Soini Y, Paakko P, Hirvikoski P, Kang SW, Saily M and Kinnula VL: Peroxiredoxins, a novel protein family in lung cancer. Int J Cancer 111: 514-521, 2004. (Pubitemid 39045317)
8. Kim HJ, Chae HZ, Kim YJ, Kim YH, Hwangs TS, Park EM and Park YM: Preferential elevation of Prx I and Trx expression in lung cancer cells following hypoxia and in human lung cancer tissues. Cell Biol Toxicol 19: 285-298, 2003. (Pubitemid 38002149)
9. Chang JW, Lee SH, Jeong JY, Chae HZ, Kim YC, Park ZY and Yoo YJ: Peroxiredoxin-I is an autoimmunogenic tumor antigen in non-small cell lung cancer. FEBS Lett 579: 2873-2877, 2005.
10. Chen MF, Keng PC, Shau H, Wu CT, Hu YC, Liao SK and Chen WC: Inhibition of lung tumor growth and augmentation of radiosensitivity by decreasing peroxiredoxin I expression. Int J Radiat Oncol Biol Phys 64: 581-591, 2006. (Pubitemid 43083448)
11. Kim YJ, Lee WS, IP C, Chae HZ, Park EM and Park YM: Prx1 suppresses radiation-induced c-Jun NH2-terminal kinase signaling in lung cancer cells through interaction with the glutathione S-transferase Pi/c-Jun NH2-terminal kinase complex. Cancer Res 66: 7136-7142, 2006.
12. Gligorov J and Lotz JP: Preclinical pharmacology of the taxanes: implications of the differences. Oncologist 9 (Suppl 2): S3-S8, 2004.
13. Posner MR: Docetaxel in squamous cell cancer of the head and neck. Anticancer Drugs 12 (Suppl 1): S21-S24, 2001.
14. Rowinsky EK: The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu Rev Med 48: 353-374, 1997.
15. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, Levitan N, Gressot L, Vincent M, Burkes R, Coughlin S, Kim Y and Berille J: Prospective randomized trial of docetaxel versus best supportive care in patients with nonsmall-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18: 2095-2103, 2000. (Pubitemid 30324363)
16. Jordan MA and Wilson L: Microtubules as a target for anticancer drugs. Nat Rev Cancer 4: 253-265, 2004. (Pubitemid 38525281)
17. Bhalla KN: Microtubule-targeted anticancer agents and apoptosis. Oncogene 56: 9075-9085, 2003.
18. Haldar S, Chintapalli J and Croce CM: Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 56: 1253-1255, 1996. (Pubitemid 26080965)
19. Haldar S, Basu A and Croce CM: Bcl2 is the guardian of microtubule integrity. Cancer Res 57: 229-233, 1997. (Pubitemid 27038278)
20. Lee LF, Li G, Templeton DJ and Ting JP: Paclitaxel (Taxol)- induced gene expression and cell death are both mediated by the activation of c-Jun NH2-terminal kinase (JNK/SAPK). J Biol Chem 273: 28253-28260, 1998. (Pubitemid 28496124)
21. Amato SF, Swart JM, Berg M, Wanebo HJ, Mehta SR and Chiles TC: Transient stimulation of the c-Jun-NH2-terminal kinase/activator protein 1 pathway and inhibition of extracellular signal-regulated kinase are early effects in paclitaxel-mediated apoptosis in human B lymphoblasts. Cancer Res 58: 241-247, 1998. (Pubitemid 28047062)
22. Mhaidat NM, Wang Y, Kiejda KA, Zhang XD and Hersey P: Docetaxel-induced apoptosis in melanoma cells is dependent on activation of caspase-2. Mol Cancer Ther 6: 752-761, 2007. (Pubitemid 46332476)
23. Mhaidat NM, Zhang XD, Jiang CC and Hersey P: Docetaxel-induced apoptosis of human melanoma is mediated by activation of c-Jun NH2-terminal kinase and inhibited by the mitogen-activated protein kinase extracellular signal-regulated kinase 1/2 pathway. Clin Cancer Res 13: 1308-1314, 2007. (Pubitemid 46424072)
24. MacKeigan JP, Taxman DJ, Hunter D, Earp HS III, Graves LM and Ting JP: Inactivation of the antiapoptotic phosphatidylinositol 3-kinase-Akt pathway by the combined treatment of taxol and mitogen-activated protein kinase kinase inhibition. Clin Cancer Res 8: 2091-2099, 2002. (Pubitemid 34753578)
25. Hu L, Hofmann J, Lu Y, Mills GB and Jaffe RB: Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res 62: 1087-1092, 2002. (Pubitemid 34160292)
26. Iwao-Koizumi K, Matoba R, Ueno N, Kim SJ, Ando A, Miyoshi Y, Maeda E, Noguchi S and Kato K: Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol 23: 422-431, 2005. (Pubitemid 46224217)
27. Chhipa RR, Lee KS, Onate S, Wu Y and Ip C: Prx1 enhances androgen receptor function in prostate cancer cells by increasing receptor affinity to dihydrotestosterone. Mol Cancer Res 7: 1543-1552, 2009.
28. Crissman HA and Steinkamp JA: Cell cycle-related changes in chromatin structure detected by flow cytometry using multiple DNA fluorochromes. Eur J Histochem 37: 129-138, 1993.
29. Lowry OH, Rosebrough NJ, Farr AL and Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275, 1951.
30. Dumontet C and Sikic BI: Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport and cell death. J Clin Oncol 17: 1061-1070, 1999. (Pubitemid 29109340)
31. Montegomery RB, Bonham M, Nelson PS, Grim J, Makary E, Vessella R and Stahl WL: Estrogen effects on tubulin expression and taxane mediated cytotoxicity in prostate cancer cells. Prostate 65: 141-150, 2005. (Pubitemid 41362281)
32. Cip1, which inhibits p34Cdc2 kinase. Mol Cell 2: 581-591, 1998.
33. Wu JD, Haugk K, Coleman I, Woodke L, Vessella R, Nelson P, Montgomery RB, Ludwig DL and Plymate SR: Combined in vivo effect of A12, a type 1 insulin-like growth factor receptor antibody and docetaxel against prostate cancer tumors. Clin Cancer Res 12: 6153-6160, 2006. (Pubitemid 44703781)
34. Xing H, Weng D, Chen G, Tao W, Zhu T, Yang X, Meng L, Wang S, Lu Y and Ma D: Activation of fibronectin/PI-3K/Akt2 leads to chemoresistance to docetaxel by regulating survivin protein expression in ovarian and breast cancer cells. Cancer Lett 261: 108-119, 2008. (Pubitemid 351192224)
35. Kosaka T, Miyajima A, Shirotake S, Suzuki E, Kikuchi E and Oya M: Long-term androgen ablation and docetaxel up-regulate phosphorylated Akt in castration resistant prostate cancer. J Urol 185: 2376-2381, 2011.
36. Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y, Tran H, Ross SE, Mostoslavsky R, Cohen HY, Hu LS, Cheng HL, Jedrychowski MP, Gygi SP, Sinclair DA, Alt FW and Greenberg ME: Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 303: 2011-2015, 2004. (Pubitemid 38393275)
37. Biggs WH III, Meisenhelder J, Hunter T, Cavenee WK and Arden KC: Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor of FKHR1. Proc Natl Acad Sci USA 96: 7421-7426, 1999. (Pubitemid 29299677)
38. Kops GJ and Burgering BM: Forkhead transcription factors: new insights into protein kinase B (c-akt) signaling. J Mol Med 77: 656-665, 1999. (Pubitemid 29500958)
39. Nakae J, Park BC and Accili D: Insulin stimulates phosphorylation of the forkhead transcription factor FKHR on serine 253 through a Wortmannin-sensitive pathway. J Biol Chem 274: 15982-15985, 1999.
40. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J and Greenberg ME: Akt promotes cell survival by phosphorylating and inhibiting a Forehead transcription factor. Cell 96: 857-868, 1999. (Pubitemid 29165088)
41. Suhara T, Kim HS, Kirshenbaum LA and Walsh K: Suppression of Akt signaling induces Fas ligand expression: involvement of caspase and Jun kinase activation in Akt-mediated Fas ligand regulation. Mol Cell Biol 22: 680-691, 2002. (Pubitemid 34027511)
42. Dijkers PF, Medema RH, Lammers JW, Koenderman L and Coffer PJ: Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. Curr Biol 10: 1201-1204, 2000.
43. Modur V, Nagarajan R, Evers BM and Milbrandt J: FOXO proteins regulate tumor necrosis factor-related apoptosis inducing ligand expression. Implications for PTEN mutation in prostate cancer. J Biol Chem 277: 47928-47937, 2002. (Pubitemid 36159321)
44. Kavurma MM and Khachigian LM: Signaling and transcriptional control of Fas ligand gene expression. Cell Death Differ 10: 36-44, 2003. (Pubitemid 36511831)
45. Lee YJ, Park MY and Kang YA: Enhancement of sensitivity of human lung cancer cell line to TRAIL and gefitinib of IGF-1R blockade. Tuberc Respir Dis 63: 42-51, 2007.
46. Greer EL and Brunet A: FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 24: 7410-7425, 2005. (Pubitemid 41637981)
47. Sunters A, Femandez de Mattos S, Stahl M, Brosens JJ, Zoumpoulidou G, Saunders CA, Coffer PJ, Medema RH, Coombes RC and Lam EW: FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines. J Biol Chem 278: 49795-49805, 2003. (Pubitemid 37548813) Welfare